With 167 new RNA developers and 225 clinical trials initiated in 2022 alone, the therapeutic impact of RNA goes beyond mRNA vaccines.
Our mission is to leverage disruptive RNA technologies with optimized formulation, targeted delivery and scale up manufacturing to progress safe, effective and accessible therapeutics and vaccines to treat infectious diseases, oncology and beyond.
Delivering Safe & Effective RNA Therapies & Vaccines to Patients Faster
Following a surge in activity triggered by the success of RNA vaccines for SARS-CoV-2, RNA therapies have undergone a huge wave of innovation and investment. With the ability to target previously undruggable pathways, as well as recent improvements in delivery mechanisms, nucleic acid modifications and modality types, RNA therapies promise to improve the patient outcomes for a wide range of diseases.
From exclusive industry dedicated conferences, RNA-specific clinical trial and drug data and year-round knowledge sharing and problem-solving expert networks, we provide a diverse set of opportunities to stay up to date with scientific advancements, solve shared challenges and gain the clarity of insight you need to accelerate the delivery of RNA therapies and vaccines to patients faster.
Featured RNA Therapy Products
mRNA Quality Control & Comparability Summit
3rd mRNA-Based Therapeutics Summit
Make Faster, Better Drug Development Decisions
Premium Insight and Meaningful Connections for Biopharma
Expert-driven, Life Science Market Intelligence Solutions
Premium Insight, Collaborative Learning & Mission-Focused Connections for Biopharma
Get in touch
We speak to hundreds of biopharmaceutical experts from industry and academia every day. We would love for you to be one of them. Contact us to discover how our events can accelerate your drug development.
Standard Form - RNA Therapy
"*" indicates required fields